ACEL Financial Facts
Interest expense, related party: -6.95KState tax expense (benefit): 0
See Full Income Statement
Total Current Assets: 839.06K
Deferred financing costs: 0
See Full Balance Sheet
Tamir Biotechnology, Inc. (ACEL) Earnings
|
Expand Research on ACEL
| Next EPS Date | 8/5/26 | EPS Growth Rate | +150.0% |
|---|---|---|---|
| Average EPS % Beat Rate | -32.5% | Revenue Growth Rate | +5.9% |
| Average % Move 1-Wk after EPS | -1.2% | Normal Earnings Time | After Close |
| Date | Qtr | EPS | Cons. | Surprise | Revs | Cons. | Gd. | 1-Week % | 1-Day % | Details | |
|---|---|---|---|---|---|---|---|---|---|---|---|
8/5/26  |
Q226 | N/A | $0.20 | N/A | N/A | $355.6M | N/A | N/A | N/A | ||
| 5/5/26 | Q126 | $0.17 | $0.20 | -$0.03 | $352M | $341.74M | N/A |  | | Details | |
| 3/3/26 | Q425 | $0.00 | N/A | N/A | $341.45M | $335.27M | N/A | | | Details | |
| 11/4/25 | Q325 | $0.16 | $0.21 | -$0.05 | $329.7M | $327.95M | N/A | | | Details | |
| 8/5/25 | Q225 | $0.08 | $0.21 | -$0.13 | $335.9M | $328.85M | N/A | | | Details | |
| 5/5/25 | Q125 | $0.17 | $0.24 | -$0.07 | $323.9M | $310.34M | N/A | | | Details | |
| 2/27/25 |
Q424 | N/A | $0.20 | N/A | N/A | $304.11M | N/A | N/A | N/A | ||
| 10/30/24 | Q324 | $0.06 | $0.20 | -$0.14 | $302.22M | $297.03M | N/A | | | Details |
